Roivant Sciences (ROIV) CEO sells 289,774 shares around $29

Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share, totaling approximately $8.45 million. The transactions occurred between $28.98 and $29.36, and after these sales, Gline directly owns 16,736,116 common shares of ROIV. This insider activity was disclosed in a Form 4 filing and is considered very negative in sentiment according to Rhea-AI.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin